Latest: FDA Approves New Biosimilar for Oncology Treatment

NeuroVoices: John Hey, PhD, on Alzheimer Agent Valiltramiprosate and Its Promise in Mild Cognitive Impairment

by Neurology Live

13 September, 2025

0 Mins

The chief scientific officer at Alzheon discussed the mechanism of valiltramiprosate and new data on toxic amyloid oligomers presented at the recently concluded Alzheimer’s Association International Conference.

Tags:

Author

Neurology Live

Parents urged to book vaccine appointments for children in summer holidays

Rapid mass spectrometry could detect harmful algae before they pose a threat

📢

300x250 Banner

NeuroVoices: John Hey, PhD, on Alzheimer Agent Valiltramiprosate and Its Promise in Mild Cognitive Impairment

Tags:

Neurology Live

Parents urged to book vaccine appointments for children in summer holidays

Rapid mass spectrometry could detect harmful algae before they pose a threat

Recent Content

COPD Biologics: Early Treatment Insights

Antihypertensive Medication Guidelines

Juvenile Arthritis Care Transition